Nanexa
1,635
SEK
-9,67 %
NANEXA
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Mindre end 1K følgere
-9,67%
-24,31%
-29,53%
+15,14%
+75,05%
+58,74%
-56,63%
-82,54%
-80,01%
Nanexa is a drug delivery company with a proprietary platform that is used for the formulation of injectable depot drugs that create a supply of drugs to the blood. The PharmaShell process is based on ALD (Atomic Layer Deposition) technology, which encloses pharmaceutical particles with a thin shell and creates opportunities for pharmaceutical companies to develop new products. Nanexa has cooperation with several pharmaceutical companies, mainly around the Nordic market.
Læs mereMarkedsværdi
221,86 mio. SEK
Aktieomsætning
2,49 mio. SEK
Omsætning
29,33 mio.
EBIT %
-261,27 %
P/E
-
Udbytteafkast, %
-
Finanskalender
19.2
2025
Årsrapport '24
ViserAlle indholdstyper
Nanexa carries out a directed issue of units amounting to SEK 35 million and takes up a loan of SEK 20 million
Emergers: Equity Research | Nanexa AB: Phase I results position NEX-22 for licensing opportunities and a head start in long-acting GLP-1
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools